TY - JOUR
T1 - Prazosin improves atherogenic index and inhibits the deleterious effect of dihydrochlorothiazide in patients with essential hypertension
AU - Farsang, C.
AU - Peter, M.
AU - Balas-Eltes, A.
AU - Feher, J.
PY - 1987
Y1 - 1987
N2 - Twenty-three patients with essential hypertension were treated consecutively with prazosin or dihydrochlorothiazide or the combination of the two, each treatment period lasting for three months. Blood pressure, heart rate (HR), serum levels of total cholesterol, triglycerides, HDL-c and LDL-c, uric acid, glucose, Na, and K were measured during the baseline and at the end of each treatment period. Both prazosin and dihydrochlorothiazide (THI) decreased blood pressure but the effect of the combination was more pronounced than that of the monotherapies. Prazosin had no effect on the plasma level of total cholesterol, triglycerides, uric acid, Na, K, and glucose but increased HDL-c, decreased LDL-c, and thereby significantly improved (decreased) atherogenic index (total cholesterol/HDL-c). THI increased total cholesterol, triglycerides, LDL + VLDL-c, glucose, and uric acid; decreased HDL-c and K levels; and significantly increased the atherogenic index. Prazosin neutralized the effects of THI on total cholesterol, triglycerides, HDL-c, and on LDL + VLDL-c but not on glucose, uric acid, or K. These results suggest that the effects of THI on plasma lipids may be mediated by α1-adrenoceptor-related mechanisms but the effects on glucose, uric acid, and K probably may not be mediated by these mechanisms.
AB - Twenty-three patients with essential hypertension were treated consecutively with prazosin or dihydrochlorothiazide or the combination of the two, each treatment period lasting for three months. Blood pressure, heart rate (HR), serum levels of total cholesterol, triglycerides, HDL-c and LDL-c, uric acid, glucose, Na, and K were measured during the baseline and at the end of each treatment period. Both prazosin and dihydrochlorothiazide (THI) decreased blood pressure but the effect of the combination was more pronounced than that of the monotherapies. Prazosin had no effect on the plasma level of total cholesterol, triglycerides, uric acid, Na, K, and glucose but increased HDL-c, decreased LDL-c, and thereby significantly improved (decreased) atherogenic index (total cholesterol/HDL-c). THI increased total cholesterol, triglycerides, LDL + VLDL-c, glucose, and uric acid; decreased HDL-c and K levels; and significantly increased the atherogenic index. Prazosin neutralized the effects of THI on total cholesterol, triglycerides, HDL-c, and on LDL + VLDL-c but not on glucose, uric acid, or K. These results suggest that the effects of THI on plasma lipids may be mediated by α1-adrenoceptor-related mechanisms but the effects on glucose, uric acid, and K probably may not be mediated by these mechanisms.
UR - http://www.scopus.com/inward/record.url?scp=0023613804&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023613804&partnerID=8YFLogxK
U2 - 10.1097/00005344-198709002-00040
DO - 10.1097/00005344-198709002-00040
M3 - Article
C2 - 2455187
AN - SCOPUS:0023613804
SN - 0160-2446
VL - 10
SP - S240-S243
JO - Journal of Cardiovascular Pharmacology
JF - Journal of Cardiovascular Pharmacology
IS - SUPPL. 12
ER -